Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of SR604 injection in congenital factor VII deficiency
CTR20262597Phase 2Active
- Sponsor
- Shanghai RAAS
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SR604 in congenital factor VII deficiency, sponsored by Shanghai RAAS. Primary endpoint: Annualized total treated bleeding rate. Started Jul 2026; status: active.
02
Drugs
SR604
03
Conditions
congenital factor VII deficiency
Beyond the preview
Go deeper on CTR20262597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262597.